PDF Print

Research Study


Participants Invited to Take Part in a Clinical Research Study for Moderate to Severe Eczema 

 

Participants are invited to take part in “AD Up” (IRB # STU00207896), a clinical research study evaluating the efficacy and safety of an oral study drug “upadacitinib” in combination with topical corticosteroids (TCS) for the treatment of atopic dermatitis (AD).

The trial will consist of a screening period of 35 days, a dosing period of up to 2.5 years, and a follow-up period of 30 days after the last study drug dose for the assessment of safety.

Participants must be between the ages of 12 and 75, and have a diagnosis of AD for at least 3 years prior to participating in the study. Participants will also be required to have a recent history of inadequate response or have an intolerance to topical treatment with topical medication within 6 months prior to the baseline visit. AD involvement of 10% or more body surface area is also a requirement of this study.

Participation will be compensated.

The study will take place at 676 N. St. Clair Street, Suite 1600, Chicago, IL 60611. 

To contact a member of the research team- 
Call: 312-503-5945 
Email: [email protected] 

(IRB # STU00207913)
Principal Investigator: Jonathan Silverberg, MD, PhD, MPH

CLICK HERE to view brochure

Last Updated on Saturday, March 23, 2019 10:04 PM